Sana Biotechnology Inc vs Toyota Motor Corp — how do they compare? Sana Biotechnology Inc trades at $3.81 (market cap $1.13B), while Toyota Motor Corp trades at $188.86 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 196.3× Sana Biotechnology Inc's market cap, and Toyota Motor Corp pays a 3.3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TM | |
|---|---|---|
Market Cap | $1.13B | $221.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $248.29 |
52-Week Low | $2.68 | $166.50 |
Enterprise Value | $1.05B | $414.06B |
Dividend Yield | — | 3.3% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Toyota Motor (TM) trades at $188.97, up 0.1% on the day, with a bullish technical signal from moving averages. The stock presents attractive valuation metrics, including a P/E of 8.53 and P/B of 0.95, trading below book value. Recent quarterly earnings have consistently beaten expectations, though Q1 2026 results missed estimates due to higher costs, as reported by Zacks Investment Research on August 6, 2026. Cash flow trends show volatility, with a net outflow in 2025 but a projected recovery in 2026.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside, but risks include recall costs, China sales weakness, and margin pressure. Institutional sentiment is cautiously optimistic, with no sell ratings among covered analysts.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →